<DOC>
	<DOCNO>NCT03033823</DOCNO>
	<brief_summary>This study examine efficacy oral magnesium supplementation adjuvant therapy decrease intensity alcohol withdrawal symptom among inpatient require pharmacological treatment AWS . This double blind randomize multicenter clinical trial plan treat half participant usal plus placebo half usual plus magnesium .</brief_summary>
	<brief_title>MAGnesium Adjunction Alcohol Withdrawal Syndrome : Multicenter Assessment ( MAGMA )</brief_title>
	<detailed_description>Alcohol withdrawal syndrome ( AWS ) frequent potentially fatal outcome . It crucial treat AWS order reduce symptom severity , prevent severe complication increase patient motivation maintain long-term alcohol abstinence . Clarify relevance oral magnesium supplementation routine adjuvant therapy AWS give rise major evolution guideline regard management alcohol use disorder make AWS comfortable hundred thousand patient . Magnesium act competitor glutamate NMDA receptor bind site , limit glutamate toxicity lead AWS . Previous finding suggest correlation AWS intensity hypomagnesaemia degree , increase risk severe AWS ( i.e . delirium tremens seizure ) deep depletion . In addition magnesium role glutamatergic modulator via NMDA-receptor antagonism activity , magnesium may also modulate GABAergic neurotransmission affect numerous transduction pathway , include proteinkinase C , possibly influence access corticosteroid brain . Moreover , magnesium find cofactor require thiamine-dependent enzyme whereas thiamine supplementation crucial prevent Wernicke 's encephalopathy treatment AWS . Finally , magnesium supplementation could help reduce benzodiazepine use . The primary endpoint between-group absolute difference revise clinical institute withdrawal assessment alcohol scale ( CIWA-Ar ) score change baseline , 3 day randomization . The secondary endpoint : Total benzodiazepine consumption compare experimental control group throughout duration study ( i.e . 15 day ) ; b Time require obtain total score 0 CIWA-Ar compare experimental control group ; c Rate patient experience seizure delirium tremens study compare intervention control group ; Stratify result Primary endpoint follow score Charlson Comorbidity Index ; e Stratify result Primary endpoint age ; f Number participant leave hospital medical advice study compare experimental control group ; g Number participant make appointment addiction unit study ( i.e . last follow-up point , 15 day baseline ) , compare experimental control group stratification follow AUD duration number previous addiction healthcare ; h Patient Satisfaction Questionnaire-18 ( PSQ-18 ) score last follow-up point ( i.e . day baseline ) compare experimental control group ; Total plasmatic magnesium concentration change baseline , 3 day baseline , 7 day baseline ; j Rate adverse event occur study incidence compare experimental control group ; Practical procedure : Patients recruit inpatient , hospitalize whatever main reason hospitalization ( i.e . alcohol withdrawal syndrome reason ) . Inclusion visit start signature informed consent , confirm eligibility finally , end randomization administration first dose treatment . Patients follow 15 day baseline . Total plasmatic magnesium concentration dose baseline , 3 day 7 day . In addition CIWA-Ar AUDIT , follow assessment perform baseline : Charlson comorbidity index , DIGS , SCL-90 , MINI . We use tablet 465.4 mg magnesium lactate dehydrate ( MagnespasmylÂ© ) , correspond 47.4mg magnesium ( i.e . 1.9mmol magnesium per tablet ) . These tablet prescribe follow : 3 tablet three time per day . In case diarrhea , nearly half-dosage used end follow-up ( i.e . 189.6mg per day , 3 time day follow : 1 tablet , 2 tablet , 1 tablet ) . Patients informed treatment take meal avoid sodas study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<criteria>Adult inpatient , men woman ( i.e . age &gt; 18 year &lt; 75 year ) ; Current AWS accord DSM5 criterion ; Score revise clinical institute withdrawal assessment alcohol scale ( CIWAAr ) &gt; 8 ; Written inform consent participate study ; Affiliation French Social Security Health Care plan . Age le 18 great 75 ; Hemodynamic failure ; Arythmia ; Lack fulfil AWS criterion accord DSM5 ; Score revise clinical institute withdrawal assessment alcohol scale ( CIWAAr ) &lt; =8 ; Other current substance use disorder regard DSM5 criterion , include benzodiazepine substance use disorder except tobacco . In addition benzodiazepine substance use disorder , follow criterion inappropriate use benzodiazepine relatedbenzodiazepine hypnotic also consider noninclusion criterion : overthecounter consumption ; consumption outside indication market authorization ; excessive dosage duration regard guideline . Licit illicit substance consumption fulfil substance use disorder DSM5 criterion consider noninclusion criterion ( e.g . cannabis consumption without sufficient criterion diagnose substance use disorder regard DSM5 criterion ) ; Pregnancy breastfeeding ; Unable take oral medication ; Creatinine clearance &lt; 30mL/min accord CockcroftGault Equation ; Cognitive disorder impair informed consent , include dementia ( except acute withdrawal delirium ) ; Psychiatric disorder require hospitalization specific care emergency ( e.g . suicidal crisis , acute psychotic episode ) ; Magnesium supplementation ( regardless type delivery ) within 3 month prior inclusion ; Actual quinidine intake ; No write informed consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Delirium</keyword>
	<keyword>Magnesium Deficiency</keyword>
</DOC>